



1202892

August 8, 2021

PMPRB Consultation Team  
Patented Medicine Prices Review Board  
Box L40 333 Laurier Ave West  
Suite 1400  
Ottawa ON K1P 1C1  
pmprb.consultations.cepmb@pmprb-cepmb.gc.ca

Dear PMPRB:

I am writing to restate my strong support for the full implementation of the regulatory changes proposed by the Federal Government for the Patented Medicine Prices Review Board (PMPRB) to better address excessive drug prices in Canada. British Columbia has previously expressed our support.

The regulatory mandate of the PMPRB is to protect Canadians against excessive prices charged by patentees for patented medicines. While the PMPRB was formed over 30 years ago, Canada's patented medicine prices remain among the highest in the world. The proposed modernization should provide the PMPRB with updated tools to better protect Canadians and public drug plans from excessive prices for patented medicines. While BC is disappointed to hear of a further delay of the implementation of the modernized regulations, we are hopeful that they will be implemented by January 1, 2022 without any further delays.

I strongly urge the Federal Government to implement these proposed regulatory amendments without any further delays.

Sincerely,

Mitch Moneo  
Assistant Deputy Minister  
Pharmaceutical, Laboratory and Blood Services Division, Ministry of Health